ABSTRACT
BACKGROUND: Targeted oncology therapy with inhibitors of epidermal growth factor receptor is associated with numerous cutaneous side effects. Acneiform eruptions are the most frequent skin toxicities reported. They may lead to impairment of patients' quality of life and sometimes may even become severe enough to necessitate the interruption or cessation of therapy. OBJECTIVE: To assess the possible effect of topical phytomenadione (vitamin K1 ) pre-treatment in diminishing the extent and severity of acne-like follicular rash associated with epidermal growth factor receptor inhibitor therapy. METHODS: A series of 20 patients with colorectal cancer or head and neck cancer were pre-treated with phytomenadione cream (0.05% in seven patients and 0.1% in 13 patients), starting morning before the first infusion of cetuximab or panitumumab, and followed up for the development of therapy-associated folliculitis. The cream was prepared from phytomenadione solution added to a hydrophilic cream base, oil in water, to obtain the concentration of 0.05% or 0.1%. RESULTS: Majority of patients (15 out of 20, 75%) pre-treated with phytomenadione cream experienced only mild, grade I acneiform eruptions. Five patients (25%) had grade II rash, which included two of seven patients pre-treated with 0.05% phytomenadione cream and three of 13 patients who used 0.1% phytomenadione cream. Topical phytomenadione cream was well tolerated and no abnormalities in blood coagulation were observed. CONCLUSIONS: Topical pre-treatment with phytomenadione cream might become useful in epidermal growth factor inhibitor-associated acneiform eruptions.
Subject(s)
Antibodies, Monoclonal, Humanized/adverse effects , Antibodies, Monoclonal/adverse effects , ErbB Receptors/antagonists & inhibitors , Folliculitis/drug therapy , Vitamin K 1/therapeutic use , Adult , Aged , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized/therapeutic use , Antineoplastic Agents/adverse effects , Antineoplastic Agents/therapeutic use , Cetuximab , Colorectal Neoplasms/drug therapy , Female , Folliculitis/chemically induced , Head and Neck Neoplasms/drug therapy , Humans , Male , Middle Aged , PanitumumabABSTRACT
Segmental Darier's disease is a rare clinical variant of autosomal dominant Darier's disease (keratosis follicularis) exhibiting eruptions in a unilateral arrangement following the lines of Blaschko. It occurs in approximately 10% of patients with Darier's disease. We report two cases of type 1 segmental Darier's disease that appeared a few months after childbirth; in one case, recurrence of the disease occurred after tubal ligation.
Subject(s)
Darier Disease/pathology , Puerperal Disorders/pathology , Sterilization, Tubal/adverse effects , Adult , Darier Disease/etiology , Female , Humans , Pregnancy , Recurrence , Skin/pathologySubject(s)
Acne Vulgaris/drug therapy , Benzoyl Peroxide/administration & dosage , Peroxides/administration & dosage , Resorcinols/administration & dosage , Salicylates/administration & dosage , Administration, Topical , Benzoyl Peroxide/therapeutic use , Humans , Resorcinols/therapeutic use , Salicylates/therapeutic use , Time FactorsABSTRACT
A modification of the "skin window" method is proposed for investigation of delayed hypersensitivity in patients with tumors. The principle of the modified method consists in an antigen injection into the site of lesion. Patients with tumors showed a strikingly lowered lymphoid cells and eosinophilic and basophilic granulocytes than the controls.
